Loading clinical trials...
Loading clinical trials...
Phase II/III Study of Chemotherapy Combination With Autologous Cytokine-Induced Killer Cell Immunotherapy in Stage IIIb-IV Squamous Non-Small-Cell Lung Cancer
Conditions
Interventions
CIK cell
Gemcitabine Injection
+1 more
Locations
1
China
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, China
Start Date
December 1, 2014
Primary Completion Date
December 1, 2018
Completion Date
December 1, 2018
Last Updated
November 5, 2019
NCT04929028
NCT06980038
NCT07190248
NCT05039801
NCT06305754
NCT07042295
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions